Ica Group Wealth Management, LLC Corvus Pharmaceuticals, Inc. Transaction History
Ica Group Wealth Management, LLC
- $493 Million
- Q1 2024
A detailed history of Ica Group Wealth Management, LLC transactions in Corvus Pharmaceuticals, Inc. stock. As of the latest transaction made, Ica Group Wealth Management, LLC holds 165 shares of CRVS stock, worth $300. This represents 0.0% of its overall portfolio holdings.
Number of Shares
165Holding current value
$300% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding CRVS
# of Institutions
51Shares Held
18.3MCall Options Held
29.9KPut Options Held
30.2K-
Orbimed Advisors LLC San Diego, CA6.94MShares$12.6 Million0.28% of portfolio
-
Adams Street Partners LLC Chicago, IL3.28MShares$5.96 Million2.56% of portfolio
-
Samlyn Capital, LLC New York, NY2.35MShares$4.27 Million0.07% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.49MShares$2.72 Million0.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny637KShares$1.16 Million0.0% of portfolio
About Corvus Pharmaceuticals, Inc.
- Ticker CRVS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 46,553,500
- Market Cap $84.7M
- Description
- Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase Ib/II clinical trial for non-small cell lung cancer and head and neck cancers. The compan...